Unlocking new frontiers: DNA nanotechnology’s impact on acute kidney injury diagnosis and treatment

Acute kidney injury (AKI) serves as an independent risk factor for chronic kidney disease (CKD) and hastens its progression. However, effective early diagnosis and treatment methods for AKI are still limited in clinical practice. There is a pressing need to develop fast, effective, and noninvasive diagnostic methods for AKI, as well as treatments that reduce nephrotoxicity. DNA nanotechnology, utilizing the programmable properties of DNA to engineer nanostructures and nanodevices, has achieved significant advancements in disease diagnosis and treatment. The application of DNA nanotechnology for kidney disease, particularly AKI, has been increasingly explored. This review encompasses the advancement of rapid and highly sensitive detection methods for AKI biomarkers, alongside the development of targeted drug delivery systems to the kidneys. These innovations facilitate precise treatment while minimizing adverse drug effects. The review underscores the progress in employing DNA nanotechnology for AKI diagnosis and treatment. Initially, we examine DNA nanotechnology-based strategies for AKI diagnosis, with an emphasis on biomarker detection. Subsequently, we delve into the therapeutic applications of DNA nanotechnology in AKI, highlighting targeted drug delivery and reduced toxicity. Finally, we offer insights into the challenges and opportunities associated with the clinical application of DNA nanotechnology in AKI management.